



We heal and inspire the human spirit.

To: All IPA Administrators and Medical Directors
From: IEHP – Provider Relations
Date: March 11, 2024
Subject: **REVISED/RETIRED – UM Authorization Guidelines**

IEHP’s Guideline Review Committee has approved the following authorization guideline updates/changes, effective 2/28/2024:

Guideline #	Guideline Title	Degree of Change	Updates/Changes
UM_OTH 09	My Path	Minor Revised	Highlights: <ul style="list-style-type: none">• Updated references
UM_OTH 18	Enhanced Care Management	Minor Revised	Highlights: <ul style="list-style-type: none">• <u>Addition</u> of the following populations of focus:• Children and Youth (July 1, 2023)• Birth Equity (January 1, 2024)• Individuals transitioning from incarceration (January 1, 2024).
UM_OTH 23	Allocation of Limited Critical Care Resources During a Public Health Emergency	Minor Revised	Highlights: <ul style="list-style-type: none">• The COVID-19 pandemic changed how we look at our critical resources. We understand that IEHP has a finite amount of medical equipment, medication, and staff in our network to utilize in the care of our Members.• A review of IEHP’s approved clinical criteria utilized for making UM decisions fails to identify guidance or direction in this area (i.e. CMS, Medi-Cal, MCG, Apollo, etc.).• Recommend continuing applying IEHP’s UMSC guideline in the allocation of critical resources for both our Medicare and Medi-Cal LOB. For this review cycle, only references have been updated.
UM_OTH 22	Biosimilar Products	Retired	Highlights: <ul style="list-style-type: none">• IEHP’s biosimilar policy requires trial and failure on 2 biosimilar drugs before trying the reference product.• The DMHC APL 23-025 requires all plan to comply to the newly enacted SB 621:

Guideline #	Guideline Title	Degree of Change	Updates/Changes
			<ul style="list-style-type: none">○ Allow plans to require biosimilar trial and failure before providing coverage for the reference product.○ The plan’s requirement should not supersede a step therapy request as described in Section 1367.206(b).● IEHP recommends retiring the biosimilar policy, to be compliant with the SB 621 and to be consistent of IEHP UM criteria hierarchy.

You may access these and all other authorization guidelines at: www.providerservices.iehp.org > Resources > Providers Resources > Utilization Management Clinical Criteria

As a reminder, communications sent by IEHP can also be found at: www.providerservices.iehp.org > Provider Central > News and Updates > Notices

If you have any questions, please do not hesitate to contact the IEHP Provider Call Center at (909) 890-2054, (866) 223-4347 or email ProviderServices@iehp.org